Journal of Immunology Research

Characteristics of Immunobiology in the Tumor Microenvironment- Development of Immunotherapies


Publishing date
01 Sep 2018
Status
Published
Submission deadline
27 Apr 2018

Lead Editor

1University of Münster, Münster, Germany

2Southwest Medical University, Luzhou, China

3Navy General Hospital, Beijing, China


Characteristics of Immunobiology in the Tumor Microenvironment- Development of Immunotherapies

Description

In the last decade, immunotherapies methods have been playing a key role in the clinical treatment of cancer. It has been clearly demonstrated that the characteristics of different cancers were the basement for the specific cancer immunotherapies. Cancer cell can be attacked by immune system targeting tumor-associated antigens via active immunotherapy; moreover, antitumor responses can also be enhanced by using antibodies, lymphocytes, or cytokines via passive immunotherapies. The competence of immunotherapies, however, is largely dependent on the properties of immune response in the tumor microenvironment. Therefore, a thorough understanding of above process will help us find more effective cancer immunotherapies strategies.

The high-quality original research articles as well as review articles are invited to understand and clarify the related fundamental knowledge and underlying mechanism of immune response during the respective cancer immunotherapies process so as to explore more new therapeutic strategies and improve the clinical efficiency on cancer treatment.

Potential topics include but are not limited to the following:

  • Alteration of immune cell properties in cancer development
  • Immunomodulation of the tumor microenvironment by immunotherapy
  • Exploration of cancer immunotherapy targets
  • Combining immunotherapy and targeted therapies in cancer treatment
  • Pharmacological strategies for cancer immunotherapy

Articles

  • Special Issue
  • - Volume 2018
  • - Article ID 4602570
  • - Research Article

Integrin α9 Suppresses Hepatocellular Carcinoma Metastasis by Rho GTPase Signaling

Yan-Li Zhang | Xin Xing | ... | Xue-Li Zhang
  • Special Issue
  • - Volume 2018
  • - Article ID 9485285
  • - Research Article

PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins

Haiyan Tai | Qin Yang | ... | Congjian Xu
  • Special Issue
  • - Volume 2018
  • - Article ID 5038172
  • - Research Article

Melittin Constrains the Expression of Identified Key Genes Associated with Bladder Cancer

Zidan Jin | Jie Yao | ... | Bai Li
  • Special Issue
  • - Volume 2018
  • - Article ID 1982423
  • - Review Article

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas

Magdalena Witkowska | Piotr Smolewski
  • Special Issue
  • - Volume 2018
  • - Article ID 2834109
  • - Research Article

miR-24-3p/FGFR3 Signaling as a Novel Axis Is Involved in Epithelial-Mesenchymal Transition and Regulates Lung Adenocarcinoma Progression

Pengyu Jing | Nan Zhao | ... | Zhongping Gu
  • Special Issue
  • - Volume 2018
  • - Article ID 9585614
  • - Review Article

Immunotherapies: Exploiting the Immune System for Cancer Treatment

Jeffrey Koury | Mariana Lucero | ... | Andrew Tran
  • Special Issue
  • - Volume 2018
  • - Article ID 6202876
  • - Research Article

A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer

Wei Lv | Yamei Shen | ... | Li Zhang
  • Special Issue
  • - Volume 2018
  • - Article ID 7438608
  • - Research Article

FGFRL1 Promotes Ovarian Cancer Progression by Crosstalk with Hedgehog Signaling

Haiyan Tai | Zhiyong Wu | ... | Congjian Xu
  • Special Issue
  • - Volume 2017
  • - Article ID 3072745
  • - Research Article

Exemestane Attenuates Hepatic Fibrosis in Rats by Inhibiting Activation of Hepatic Stellate Cells and Promoting the Secretion of Interleukin 10

Ya-Hui Wang | Rong-Kun Li | ... | Zhi-Gang Zhang
  • Special Issue
  • - Volume 2017
  • - Article ID 7989020
  • - Research Article

Comparison of Myeloid Cells in Circulation and in the Tumor Microenvironment of Patients with Colorectal and Breast Cancers

Salman M. Toor | Eyad Elkord
Journal of Immunology Research
 Journal metrics
See full report
Acceptance rate11%
Submission to final decision121 days
Acceptance to publication27 days
CiteScore6.000
Journal Citation Indicator0.560
Impact Factor4.1
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.